Your browser doesn't support javascript.
loading
Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection.
Jiang, Xiao-Lin; Song, Xue-Dong; Shi, Chao; Yang, Guo-Jian; Wang, Xue-Jun; Zhang, Yu-Wei; Wu, Jie; Zhao, Lian-Xiang; Zhang, Ming-Zhu; Wang, Ming-Ming; Chen, Rui-Rui; He, Xue-Juan; Dai, Er-Hei; Gao, Hui-Xia; Shen, Yuan; Dong, Gang; Wang, Yu-Ling; Ma, Mai-Juan.
Afiliação
  • Jiang XL; Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China.
  • Song XD; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China; Department of Laboratory Medicine, Handan Central Hospital, Hebei Medical University, Handan 056001, China; Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseas
  • Shi C; Department of Infectious Disease Control and Prevention, Wuxi Center for Disease Control and Prevention, Wuxi 214023, China.
  • Yang GJ; Department of Microbiological Laboratory Technology, School of Public Health, Cheeloo College of Medicine, Shandong University, Key Laboratory of Prevention and Control of Emerging Infectious Diseases and Biosafety in Universities of Shandong, Jinan 250012, China.
  • Wang XJ; Bioinformatics Center of Academy of Military Medical Science, Beijing 100850, China.
  • Zhang YW; Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China.
  • Wu J; Department of Infectious Disease Control and Prevention, Binzhou Center for Disease Control and Prevention, Binzhou 256613, China.
  • Zhao LX; School of Public Health, Weifang Medical University, Weifang 261053, China.
  • Zhang MZ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.
  • Wang MM; Bioinformatics Center of Academy of Military Medical Science, Beijing 100850, China.
  • Chen RR; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China; School of Public Health, Zhengzhou University, Zhengzhou 450001, China.
  • He XJ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China; School of Public Health, Zhengzhou University, Zhengzhou 450001, China.
  • Dai EH; Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang 050021, China.
  • Gao HX; Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang 050021, China.
  • Shen Y; Department of Infectious Disease Control and Prevention, Wuxi Center for Disease Control and Prevention, Wuxi 214023, China. Electronic address: sarayshen@163.com.
  • Dong G; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China. Electronic address: donggang@bmi.ac.cn.
  • Wang YL; Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang 050021, China. Electronic address: 1149497466@qq.com.
  • Ma MJ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China; Department of Microbiological Laboratory Technology, School of Public Health, Cheeloo College of Medicine, Shandong University, Key Laboratory of Prevention and Control of Eme
Cell Rep ; 43(7): 114387, 2024 Jun 18.
Article em En | MEDLINE | ID: mdl-38896777
ABSTRACT
The ongoing emergence of SARS-CoV-2 variants poses challenges to the immunity induced by infections and vaccination. We conduct a 6-month longitudinal evaluation of antibody binding and neutralization of sera from individuals with six different combinations of vaccination and infection against BA.5, XBB.1.5, EG.5.1, and BA.2.86. We find that most individuals produce spike-binding IgG or neutralizing antibodies against BA.5, XBB.1.5, EG.5.1, and BA.2.86 2 months after infection or vaccination. However, compared to ancestral strain and BA.5 variant, XBB.1.5, EG.5.1, and BA.2.86 exhibit comparable but significant immune evasion. The spike-binding IgG and neutralizing antibody titers decrease in individuals without additional antigen exposure, and <50% of individuals neutralize XBB.1.5, EG.5.1, and BA.2.86 during the 6-month follow-up. Approximately 57% of the 107 followed up individuals experienced an additional infection, leading to improved binding IgG and neutralizing antibody levels against these variants. These findings provide insights into the impact of SARS-CoV-2 variants on immunity following repeated exposure.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Cell Rep Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Cell Rep Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China